NeuroMetrix (NASDAQ:NURO) Announces Earnings Results

NeuroMetrix (NASDAQ:NURO) announced its quarterly earnings data on Tuesday. The medical device company reported ($0.75) earnings per share for the quarter, RTT News reports. The business had revenue of $0.59 million during the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. During the same quarter in the previous year, the business posted ($1.66) EPS.

NeuroMetrix Stock Up 1.7 %

NURO traded up $0.06 during trading on Wednesday, hitting $3.61. The company’s stock had a trading volume of 10,835 shares, compared to its average volume of 26,236. The business’s 50 day simple moving average is $4.04 and its 200-day simple moving average is $3.88. The firm has a market cap of $7.33 million, a PE ratio of -0.65 and a beta of 2.29. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of NeuroMetrix in a research report on Monday. They issued a “sell” rating on the stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.